C
MRNA icon

Covestor’s Moderna MRNA Stock Holding History

Covestor’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12K Sell
172
-130
-43% -$6.73K 0.01% 1448
2026
Q1 		$15K Sell
302
-194
-39% -$9.05K 0.01% 1231
2025
Q4 		$15K Buy
496
+55
+12% +$1.49K 0.01% 1401
2025
Q3 		$11K Sell
441
-7
-2% -$195 0.01% 1548
2025
Q2 		$12K Buy
448
+170
+61% +$4.48K 0.01% 1479
2025
Q1 		$8K Buy
278
+3
+1% +$106 0.01% 1629
2024
Q4 		$11K Buy
275
+117
+74% +$5.59K 0.01% 1492
2024
Q3 		$11K Buy
158
+2
+1% +$184 0.01% 1501
2024
Q2 		$19K Sell
156
-257
-62% -$32.5K 0.01% 1221
2024
Q1 		$44K Sell
413
-272
-40% -$27.4K 0.03% 930
2023
Q4 		$68K Sell
685
-630
-48% -$53K 0.05% 715
2023
Q3 		$136K Buy
1,315
+1,152
+707% +$129K 0.1% 262
2023
Q2 		$20K Buy
163
+26
+19% +$3.47K 0.02% 1139
2023
Q1 		$21K Sell
137
-12
-8% -$1.98K 0.02% 986
2022
Q4 		$27K Sell
149
-137
-48% -$22.4K 0.02% 948
2022
Q3 		$34K Sell
286
-971
-77% -$147K 0.03% 847
2022
Q2 		$179K Buy
1,257
+58
+5% +$8.29K 0.14% 139
2022
Q1 		$207K Buy
1,199
+836
+230% +$141K 0.14% 143
2021
Q4 		$92K Buy
+363
New +$106K 0.13% 202

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Covestor's MRNA Position: Q2 2026 in Review

Covestor reduced its Moderna (MRNA) stake by 43% in Q2 2026, selling an estimated $6.73K and leaving 172 shares worth $12K. The position accounts for 0.01% of the portfolio, ranked #1448.

Covestor first reported a position in MRNA in Q4 2021 and has held it in 19 quarters since. The position peaked at $207K in Q1 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Covestor held 172 shares of Moderna worth $12K as of Q2 2026.
  • Covestor sold 130 Moderna shares in Q2 2026, an estimated $6.73K.
  • Moderna made up 0.01% of Covestor's portfolio in Q2 2026, its #1448 holding.
  • Covestor first reported a position in Moderna in Q4 2021 and has held it in 19 quarters since.
  • Covestor's Moderna position peaked at $207K in Q1 2022.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.